AMLOGENYX
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease. It is a spin-off from Ultragenyx Pharmaceutical.
AMLOGENYX
Industry:
Biotechnology Genetics Therapeutics
Founded:
2023-01-01
Address:
Somerville, Massachusetts, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
360 M CNY
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
VintaBio
VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.
More informations about "Amlogenyx"
Home - AmlogenyxAmlogenyx
Vision Amlogenyx is dedicated to the development of a novel gene therapy strategy to reduce amyloid accumulation in the brain in order to prevent and treat diseases like Alzheimer’s disease.See details»
About us - AmlogenyxAmlogenyx
Origin story Amlogenyx is developing a novel protease therapy shown to reduce amyloid (Aβ42) accumulation in preclinical models of Alzheimer’s disease. Amyloid accumulation has been …See details»
Amlogenyx - Crunchbase Company Profile & Funding
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease.See details»
Amlogenyx - LinkedIn
Amlogenyx is dedicated to the development of a novel gene therapy strategy to reduce amyloid accumulation in the brain in order to prevent and treat diseases like Alzheimer’s disease.See details»
Amlogenyx 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Amlogenyx. Use the PitchBook Platform to explore the full profile.See details»
Amlogenyx Inc. Closes Successful Seed Funding Led by …
Aug 2, 2024 BEVERLY HILLS, Calif., August 02, 2024--GordonMD® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. …See details»
Amlogenyx - Products, Competitors, Financials, Employees, …
Amlogenyx's headquarters is located at Somerville. What is Amlogenyx's latest funding round? Amlogenyx's latest funding round is Seed. How much did Amlogenyx raise? Amlogenyx raised …See details»
Amlogenyx, Inc. - VentureRadar
Amlogenyx, Inc., a subsidiary of Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), is dedicated to researching and developing novel gene therapies for Alzheimer’s disease and other amyloid …See details»
Amlogenyx Inc. Closes Successful Seed Funding Led by …
Aug 2, 2024 GordonMD® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a subsidiary of USee details»
Amlogenyx Closes USD14M Seed Funding - FinSMEs
Aug 5, 2024 Amlogenyx, Inc., a Beverly Hills, CA-based subsidiary of Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) which is researching and developing novel gene …See details»
Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD …
Aug 2, 2024 BEVERLY HILLS, Calif. – GordonMD ® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a …See details»
Amlogenyx - Funding, Financials, Valuation & Investors
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease.See details»
Ultragenyx Alzheimer's Spinout, AC Immune CMO Change, Splice …
Oct 19, 2023 Ultragenyx spins out new company Amlogenyx around its Alzheimer's Disease discovery, keeping their rare disease portfolio focused yet reinforcing the importance of …See details»
Myrobalan & Amlogenyx Series A for Neurodegenerative Diseases …
Jan 11, 2024 The raise was led by Cowin Venture Capital with participation from new and existing investors. Ultragenyx Alzheimer's spinout, Amlogenyx, is set to close a $50 million …See details»
Amlogenyx Inc. Closes Successful Seed Funding Led by …
Aug 2, 2024 Amlogenyx Inc., a subsidiary of Ultragenyx Pharmaceutical (NASDAQ: RARE), has successfully closed a $14 million seed funding round led by GordonMD® Global Investments …See details»
Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD …
Aug 2, 2024 BEVERLY HILLS, Calif.-- (BUSINESS WIRE)-- GordonMD ® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 …See details»
Amlogenyx - Crunchbase
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease.See details»
Ultragenyx to spin out new company around Alzheimer’s gene …
Oct 18, 2023 Ultragenyx to spin out new company around Alzheimer’s gene therapy CEO Emil Kakkis says the company’s findings are too exciting to ignore, but the “high-risk, high-return” …See details»
Amlogenyx Pursues Alzheimers Cure with New $14 Million in Seed …
Amlogenyx, a biotech company focused on novel gene therapies for Alzheimer’s disease and amyloid disorders and a subsidiary of publicly traded Ultragenyx Pharmaceutical (NASDAQ: …See details»
Exclusive: Ultragenyx secures first funds for Alzheimer’s gene …
Aug 2, 2024 Rare disease specialist Ultragenyx reeled in a $14 million seed round for its Alzheimer’s gene therapy spinout Amlogenyx, the company exclusively told Endpoints News. …See details»